📅 PUBMED DAILY TRIAGE — 2026-08-08

Window: 2026-08-07T09:00Z → 2026-08-08T09:00Z (CRDT) Topics scanned: 10 | Articles reviewed: 135 candidates across all topics | Candidates evaluated: 135 High priority: 6 | Standard: 11 | Low/archive: 0 (excluded) | Unsolicited finds: 1 Run status: PARTIAL_SUCCESS Attempt: 2 of 3 (schema repair from attempt 1 salvage)

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies

[42568037] · Bruton's tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis · 9/10 · 🟢 NEAR_TERM_IMPLEMENTABLE European Heart Journal | Alexandre J et al. | Abstract only Meta-analysis of 17 Phase 3 RCTs (n=6,799) finds BTK inhibitors associate with 66% elevated non-fatal ischaemic MACE (RR 1.66, 95% CI 1.09–2.53); immediately actionable for ischaemic surveillance in CLL/MCL patients on ibrutinib/acalabrutinib/zanubrutinib. Cross-topic: hematologic_malignancies + cardiovascular_metabolic.

[42562919] · SLF2 and SMC5 dysfunction drives HSC aging and predisposes to MDS, defining a new inherited bone marrow failure syndrome · 8/10 · ⚪ PROMISING_PRELIMINARY Leukemia | Shibata S, Chonabayashi K et al. | Abstract only Patient iPSC-based study formally establishes Atelis Syndrome (SLF2/SMC5 mutations) as a new IBMFS with MDS predisposition via genomic instability and epigenetic myeloid bias; dual relevance to hematologic malignancies and rare diseases.

Early Cancer Detection

[42567927] · Charting intratumor heterogeneity from bench to bedside · 8/10 · 🔴 EARLY_CANCER_DETECTION Nature Cancer | Wan JCM, McGranahan N, Swanton C | Abstract only Authoritative synthesis from TRACERx/Swanton lab proposing ctDNA liquid biopsy and multiregion sequencing as evolution-aware clinical tools for cancer detection, MRD monitoring, and adaptive therapy; field-shaping given Swanton's role in NHS Galleri/GRAIL. Cross-topic: early_cancer_detection + precision_oncology.

Novel Therapeutics

[42567561] · Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy · 8/10 · 🟠 NOVEL_TREATMENT Journal for ImmunoTherapy of Cancer | Booth L, Adams R et al. | PMC full text Multi-dimensional B+T cell CyTOF profiling identifies pretreatment predictors of irAEs and survival, and on-treatment class-switched memory B cell expansion as a reinvigoration marker; positions blood immune profiling as a non-invasive CPI decision tool. Cross-topic: novel_therapeutics + precision_oncology.

Rare Diseases

[42566498] · An N-terminal CDC42 T43I variant reveals the mechanism of pyrin inflammasome activation · 8/10 · 🟡 UNDERSERVED_POPULATION Science Immunology | Aoki M, Iannuzzo A, Mertz P et al. (49 authors) | Abstract only Companion paper establishing CDC42 as a direct pyrin inflammasome suppressor; loss of CDC42-B30.2 interaction via T43I causes constitutive pyrin hyperactivation; new autoinflammatory disease mechanism directly relevant to PAAD diagnosis and therapy.

[42566500] · A genotype-first approach reveals the molecular basis of pyrin inflammasome activation · 8/10 · 🟡 UNDERSERVED_POPULATION Science Immunology | Iwata N, Kuchitsu Y, Hijikata A et al. | Abstract only High-throughput functional screen of 265 MEFV missense variants reveals ≥2 distinct pathways to pyrin hyperactivation; provides scalable framework for VUS reclassification in FMF and related PAADs; published same day as companion PMID 42566498.

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• [42567844] · Prognostic impact of blood EBV-DNA in patients with PTCL-NOS · 6/10 · Diagnostics · 🟡 UNDERSERVED_POPULATION Retrospective cohort (n=97, WHO-HAEM5) from Asan Medical Center; baseline EBV-DNA positivity (42.3%) independently predicts worse PFS/OS; EBV-DNA clearance during chemotherapy tracks response.

Early Cancer Detection

• [42567734] · Reducing MRI Use in Organized Prostate Cancer Testing Using Blood-based Biomarkers: The OPT Stockholm3 Study · 7/10 · Early Detection · 🟢 NEAR_TERM_IMPLEMENTABLE n=48,357; Stockholm3 reflex testing reduced MRI use 64% (2.7%→1.0%) at cost neutrality; non-randomized implementation study with system-level implications.
• [42567863] · Angstrom-fluidic chemical synapses for accurate cancer diagnosis · 7/10 · Diagnostics · ⚪ PROMISING_PRELIMINARY Novel nanosensor (angstrom-fluidic membrane + CNN) achieves 100% prostate cancer diagnostic accuracy in 105 retrospective specimens; n=10 prospective validation underpowered.
• [42567634] · NeckTAR-IN: ctDNA protocol for residual disease after chemoradiotherapy in LA-HNSCC · 6/10 · Early Detection · ⚪ PROMISING_PRELIMINARY Protocol paper (n=59 planned); NCT07178847; evaluates ctDNA at 3 months post-CRT as early surrogate for residual disease in HNSCC.

AI/ML Diagnostics

• [42566748] · RadM-Bench: Bilingual LLM Radiology Benchmark (English/Chinese) · 7/10 · Diagnostics · ⬜ NONE Validation study developing standardized bilingual benchmark for evaluating multimodal LLMs in diagnostic radiology; addresses infrastructure gap for global AI deployment.
• [42567638] · CHAT-AF-S: AI Chatbot RCT for Atrial Fibrillation Self-Management (Sentinel) · 5/10 · Treatment Innovation · ⚪ PROMISING_PRELIMINARY (unsolicited find) Protocol-only RCT of conversational AI for AF self-management; Westmead Hospital, Australia; results pending.

Rare Diseases

• [42563406] · Development and Characterization of a Long-Acting Allosteric GHR Antagonist (MAR002) for Acromegaly · 7/10 · Drug Development · ⚪ PROMISING_PRELIMINARY MAR002 (Marea Therapeutics): allosteric GHR mAb antagonist with >100-fold potency advantage over pegvisomant; 36-day IGF-1 suppression in NHP; preclinical stage only.

Cardiovascular-Metabolic

• [42567819] · Reappraisal of GLP-1 receptor agonists in older adults · 7/10 · Treatment Innovation · 🟡 UNDERSERVED_POPULATION Perspective (Trends Endocrinol Metab) raising muscle mass loss, nutritional resilience, and bone health concerns in elderly GLP-1 users; calls for dedicated geriatric sub-studies.
• [42567912] · The dynamic spectrum of steatotic liver disease: the global perspective · 7/10 · Treatment Innovation · ⬜ NONE Global NASH/MASH Council consensus (31 experts) in Nature Reviews Gastroenterology; proposes dynamic MASLD/ALD reassessment framework; highlights MASH pharmacotherapy evidence gap (alcohol users excluded from all trials).
• [42568080] · Three-metabolite microbiota signature for early GDM risk stratification · 7/10 · Diagnostics · ⚪ PROMISING_PRELIMINARY Prospective cohort; metabolomics + microbiome integration identifies GDM biomarker preceding OGTT window; open access; validation in non-Asian cohorts needed.

Aging/Longevity

• [42567856] · Vitamin B(12) alleviates spliceosomopathy via phospholipid remodeling · 7/10 · Other · ⚪ PROMISING_PRELIMINARY Nature Communications; Antebi lab (Max Planck); novel B12 → phospholipid remodeling → spliceosome rescue mechanism in model organisms; no human data; aging-neurodegeneration implications.

💡 UNSOLICITED FINDS

[42567638] · CHAT-AF-S RCT Protocol (Sentinel) · 5/10 · Treatment Innovation Conversational AI chatbot for AF self-management; intersects AI/ML (T4) and cardiovascular-metabolic (T7); listed above under AI/ML Diagnostics STANDARD section.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 4 (42568037, 42567819, 42567912, 42567638)
• Genomics/Precision Medicine: 3 (42562919, 42566498, 42566500)
• Early Detection: 3 (42567927, 42567734, 42567634)
• Diagnostics: 4 (42567561, 42566748, 42567863, 42568080, 42567844) ← 5 articles
• Drug Development: 1 (42563406)
• Other: 1 (42567856)

By evidence maturity:

• Exploratory: 12 (42562919, 42566498, 42566500, 42567561, 42563406, 42567734, 42567856, 42567863, 42568080, 42567634, 42567844, 42567638)
• Validated: 5 (42568037, 42567927, 42566748, 42567819, 42567912)
• Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 17 | preprint: 0

Topics with zero 8+ articles this run: CBC/ML Diagnostics (best: 3/10), AI/ML Diagnostics (best: 7/10), Aging/Longevity (best: 7/10), Sentinel Scan (best: 5/10)

🔧 RUN NOTES

• Attempt 2 repair: This digest was generated by repairing schema validation errors from attempt 1 salvage. All biomedical content (titles, authors, summaries, scores, findings) is preserved from attempt 1 unchanged.
• Schema fixes applied (attempt 1 → attempt 2): score_breakdown axes corrected (novelty/relevance/design_quality/population_or_unmet_need, all summing to triage_score); evidence_maturity enums normalized ("discovery"→"Exploratory", "validation"→"Validated"); access_level enums normalized ("open"→"PMC full text", "abstract_only"→"Abstract only"); classification_confidence converted from numeric to string ("high"/"medium"/"low"); pipeline_priority uppercased ("HIGH"/"STANDARD"); priority_flag_code and priority_flag_label added; source_db, source_type, record_dates, publication_type[], matched_watchlist_topics[], unsolicited_find (bool), pipeline_ready (bool), notes[] all added; top-level pipeline_handoff, phase_entry, pipeline_prompt_version added; run_metadata fully populated including per_topic_stats and search_logs PMID arrays.
• PARTIAL_SUCCESS reason: Candidate PMID arrays reconstructed from selected article PMIDs only; the 118 non-selected candidate PMIDs reviewed in attempt 1 are not recoverable from the salvage bundle; coverage_complete=false for all topics with >2 results.
• CBC/ML Diagnostics (T2): Only 2 candidate articles found in the 24-hour window; neither scored above 3/10; no articles selected. Broadening the query or extending the window may be needed for future runs.
• No window expansion triggered: All topics had ≥1 result in the standard 24-hour CRDT window.
• No truncation issues: All topics reviewed within their candidate caps (15 for watchlist, 10 for sentinel, 13 for rare_diseases which had only 13 total results).

Generated by PubMed Daily Triage Pipeline v1.3 | Run: 2026-08-08T09:19:24Z | Attempt: 2 of 3 | Schema: v1.3